Bladder Cancer (BC)NCT07503795
Outcomes of Definitive Radiotherapy for Bladder Cancer
An observational study of Bladder Cancer (BC), run by Sohag University at 1 site in Egypt.
Trial summary
this is an observational study for patients with non metastatic bladder cancer recieving local radical radiotherapy with curative intent recieving radical dose of radiotherapy with or without chemosensitizer Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Bladder Cancer (BC)
- What is being tested?
- Radiotherapy followed by chemotherapy
- Type of treatment
- Surgery or procedure
- How many people
- 300 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Apr 2026to 1 Jun 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Medical records of all cancer urinary bladder patients will be examined retrospectively. Histologically confirmed urothelial carcinoma or variants; definitive intent radiotherapy (≥50 Gy to bladder/pelvis); complete treatment records available.
Who may be able to join
- Histologically confirmed urothelial carcinoma or variants; definitive intent radiotherapy
Who cannot join
- Palliative radiotherapy only; prior radical cystectomy; or incomplete follow-up data.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site
Sohag University Hospitals
Sohag
heba elsagheer, 00201062162612, hebaelsagheer@yahoo.cm
About this study
Official title: Outcomes of Definitive Radiotherapy for Bladder Cancer: Real-World Experience From a Single Center
this is an observational study for patients with non metastatic bladder cancer recieving local radical radiotherapy with curative intent recieving radical dose of radiotherapy with or without chemosensitizer
- Conditions
- Bladder Cancer (BC)
- Being tested
- Radiotherapy followed by chemotherapy
- Medical subject headings
- Urinary Bladder Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Radiotherapy followed by chemotherapyRadiation
it is observational study for patient recieved defentive radiotherapy
| Study group | Role | What they receive |
|---|---|---|
| patient with bladder cancer recieving radiotherapy and the treatment related events | Not described Receives: Radiation: Radiotherapy followed by chemotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
overall survival, it is defined as time from initiation of treatment till death due to any cause or last date for follow up
Measured: one and two year
bladder intact events free survival , which is the time from initiation of radical ttt till occurrence of bladder recurrence
Measured: one and two year
disease free survival , it is time from starting radical ttt till occurrance of 1st recurrence or distant metastasis
Measured: one and two years
Secondary outcomes (1)
adverse events , it is treatment related toxicity and side effects
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Mar 2026
- Study start1 Apr 2026 (estimated)
- Primary completion1 Nov 2026 (estimated)
- Study completion1 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bladder Cancer (BC)Studies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Heba Ali Elsagheer, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07503795
- Sponsor's protocol ID
- Soh-Med-25-12___15PD
- Status last verified
- Feb 2026
- First submitted
- 5 Feb 2026
- Last updated
- 31 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 31 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Outcomes of Definitive Radiotherapy for Bladder Cancer: Real-World Experience From a Single Center
- ClinicalTrials.gov ID
- NCT07503795
- Acronym / sponsor ID
- Soh-Med-25-12___15PD
- Conditions
- Bladder Cancer (BC)
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Apr 2026 (estimated)
- Primary completion
- 1 Nov 2026 (estimated)
- Study completion
- 1 Jun 2027 (estimated)
- First posted
- 31 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
this is an observational study for patients with non metastatic bladder cancer recieving local radical radiotherapy with curative intent recieving radical dose of radiotherapy with or without chemosensitizer
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| patient with bladder cancer recieving radiotherapy and the treatment related events | – | Radiation: Radiotherapy followed by chemotherapy |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Medical records of all cancer urinary bladder patients will be examined retrospectively. Histologically confirmed urothelial carcinoma or variants; definitive intent radiotherapy (≥50 Gy to bladder/pelvis); complete treatment records available.
Key inclusion criteria (1 listed)
- Histologically confirmed urothelial carcinoma or variants; definitive intent radiotherapy
Key exclusion criteria (1 listed)
- Palliative radiotherapy only; prior radical cystectomy; or incomplete follow-up data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Radiotherapy followed by chemotherapyit is observational study for patient recieved defentive radiotherapy | Radiation | patient with bladder cancer recieving radiotherapy and the treatment related events |
Primary outcome
overall survival, it is defined as time from initiation of treatment till death due to any cause or last date for follow up
Time frame: one and two year
bladder intact events free survival , which is the time from initiation of radical ttt till occurrence of bladder recurrence
Time frame: one and two year
disease free survival , it is time from starting radical ttt till occurrance of 1st recurrence or distant metastasis
Time frame: one and two years
1 secondary outcome
adverse events , it is treatment related toxicity and side effects
Time frame: one year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Mar 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Bladder Cancer (BC)
RecruitingPhase 3
BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy
Urothelial Cancer, Metastatic Urothelial Cancer
RecruitingPhase 2
Trop2-Targeted NIR-II Fluorescent Probe for Identifying Bladder Cancer in Ex Vivo Bladder Samples
Bladder Cancer (BC), Urothelial Carcinoma (UC)
Not yet recruitingPhase 1/2
Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder Cancer
NMIBC
Not yet recruiting
Feasibility of HISA During TURBT for NMIBC
Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)
RecruitingObservational study
Trop2-targeting NIR-II Molecular Probe for Guided Identification of Non-Muscle-Invasive Bladder Cancer
Bladder Cancer (BC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Bladder Cancer (BC), run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 31 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact heba elsagheer (0201062162612, hebaelsagheer@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
overall survival, it is defined as time from initiation of treatment till death due to any cause or last date for follow up (time frame: one and two year). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Mar 2026.